Melissa J Armstrong1,2. 1. Department of Neurology, University of Florida College of Medicine, Gainesville, FL, USA. melissa.armstrong@neurology.ufl.edu. 2. Department of Neurology, University of Florida College of Medicine, McKnight Brain Institute, P.O. Box 100236, Gainesville, FL, 32610, USA. melissa.armstrong@neurology.ufl.edu.
Abstract
PURPOSE OF REVIEW: Progressive supranuclear palsy (PSP) is a 4R tau neuropathologic entity. While historically defined by the presence of a vertical supranuclear gaze palsy and falls in the first symptomatic year, clinicopathologic studies identify alternate presenting phenotypes. This article reviews the new PSP diagnostic criteria, diagnostic approaches, and treatment strategies. RECENT FINDINGS: The 2017 International Parkinson and Movement Disorder Society PSP criteria outline 14 core clinical features and 4 clinical clues that combine to diagnose one of eight PSP phenotypes with probable, possible, or suggestive certainty. Evidence supports the use of select imaging approaches in the classic PSP-Richardson syndrome phenotype. Recent trials of putative disease-modifying agents showed no benefit. The new PSP diagnostic criteria incorporating the range of presenting phenotypes have important implications for diagnosis and research. More work is needed to understand how diagnostic evaluations inform phenotype assessment and identify expected progression. Current treatment is symptomatic, but tau-based therapeutics are in active clinical trials.
PURPOSE OF REVIEW: Progressive supranuclear palsy (PSP) is a 4R tau neuropathologic entity. While historically defined by the presence of a vertical supranuclear gaze palsy and falls in the first symptomatic year, clinicopathologic studies identify alternate presenting phenotypes. This article reviews the new PSP diagnostic criteria, diagnostic approaches, and treatment strategies. RECENT FINDINGS: The 2017 International Parkinson and Movement Disorder Society PSP criteria outline 14 core clinical features and 4 clinical clues that combine to diagnose one of eight PSP phenotypes with probable, possible, or suggestive certainty. Evidence supports the use of select imaging approaches in the classic PSP-Richardson syndrome phenotype. Recent trials of putative disease-modifying agents showed no benefit. The new PSP diagnostic criteria incorporating the range of presenting phenotypes have important implications for diagnosis and research. More work is needed to understand how diagnostic evaluations inform phenotype assessment and identify expected progression. Current treatment is symptomatic, but tau-based therapeutics are in active clinical trials.
Authors: Gesine Respondek; Sigrun Roeber; Hans Kretzschmar; Claire Troakes; Safa Al-Sarraj; Ellen Gelpi; Carles Gaig; Wang Zheng Chiu; John C van Swieten; Wolfgang H Oertel; Günter U Höglinger Journal: Mov Disord Date: 2013-02-21 Impact factor: 10.338
Authors: Sara Hall; Annika Öhrfelt; Radu Constantinescu; Ulf Andreasson; Yulia Surova; Frederick Bostrom; Christer Nilsson; Widner Håkan; Hilde Decraemer; Katarina Någga; Lennart Minthon; Elisabet Londos; Eugeen Vanmechelen; Björn Holmberg; Henrik Zetterberg; Kaj Blennow; Oskar Hansson Journal: Arch Neurol Date: 2012-11
Authors: Dana Wagshal; Sethu Sankaranarayanan; Valerie Guss; Tracey Hall; Flora Berisha; Iryna Lobach; Anna Karydas; Lisa Voltarelli; Carole Scherling; Hilary Heuer; Maria Carmela Tartaglia; Zachary Miller; Giovanni Coppola; Michael Ahlijanian; Holly Soares; Joel H Kramer; Gil D Rabinovici; Howard J Rosen; Bruce L Miller; Jere Meredith; Adam L Boxer Journal: J Neurol Neurosurg Psychiatry Date: 2014-06-04 Impact factor: 10.154
Authors: Daniel R Schonhaut; Corey T McMillan; Salvatore Spina; Bradford C Dickerson; Andrew Siderowf; Michael D Devous; Richard Tsai; Joseph Winer; David S Russell; Irene Litvan; Erik D Roberson; William W Seeley; Lea T Grinberg; Joel H Kramer; Bruce L Miller; Peter Pressman; Ilya Nasrallah; Suzanne L Baker; Stephen N Gomperts; Keith A Johnson; Murray Grossman; William J Jagust; Adam L Boxer; Gil D Rabinovici Journal: Ann Neurol Date: 2017-10 Impact factor: 10.422
Authors: Oskar Hansson; Shorena Janelidze; Sara Hall; Nadia Magdalinou; Andrew J Lees; Ulf Andreasson; Niklas Norgren; Jan Linder; Lars Forsgren; Radu Constantinescu; Henrik Zetterberg; Kaj Blennow Journal: Neurology Date: 2017-02-08 Impact factor: 9.910
Authors: Nicola Spotorno; Sara Hall; David J Irwin; Theodor Rumetshofer; Julio Acosta-Cabronero; Andres F Deik; Meredith A Spindler; Edward B Lee; John Q Trojanowski; Danielle van Westen; Markus Nilsson; Murray Grossman; Peter J Nestor; Corey T McMillan; Oskar Hansson Journal: Radiology Date: 2019-10-15 Impact factor: 29.146
Authors: Alexandra Abos; Barbara Segura; Hugo C Baggio; Anna Campabadal; Carme Uribe; Alicia Garrido; Ana Camara; Esteban Muñoz; Francesc Valldeoriola; Maria Jose Marti; Carme Junque; Yaroslau Compta Journal: Neuroimage Clin Date: 2019-06-15 Impact factor: 4.881